Track Monopar Therapeutics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Monopar Therapeutics Inc. MNPR · Stock Open Monopar Therapeutics Inc. in new tab

95.72 USD
Add to portfolio
EPS
-2.20
P/B
4.95
ROE
-19.50
Beta
1.50
Target Price
127.62 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
EPS-2.20
Book Value19.50
Price to Book4.95
Debt/Equity0.16
% Insiders23.371%
Estimates
Forward P/E-50.36
Forward EPS-1.92
Target Mean Price127.62

DCF Valuation

Tweak assumptions to recompute fair value for Monopar Therapeutics Inc. (MNPR)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Monopar Therapeutics Inc. Logo Monopar Therapeutics Inc. Analysis (MNPR)

United States Health Care Official Website Stock

Is Monopar Therapeutics Inc. a good investment? Monopar Therapeutics Inc. (MNPR) is currently trading at 95.72 USD. Market analysts have a consensus price target of 127.62 USD. This suggests a potential upside from current levels.

Earnings Schedule: Monopar Therapeutics Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.92.

Investor FAQ

Does Monopar Therapeutics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Monopar Therapeutics Inc.?

Monopar Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -2.20.

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Exchange Ticker
NMS (United States) MNPR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 13, 2024 1:5
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion